āshibio, a Brisbane, CA-based biotechnology company, raised $40M in Seed and Series A funding.
Backers of the Seed funding were not disclosed. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment. In conjunction with the financing, Agent Capital Partner and Co-Founder Preston Noon has joined the Board of Directors.
The company intends to use the funds to continue to advance development of several investigative therapies including a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease characterized by severe and progressive heterotopic ossification (HO), a pathological condition that causes abnormal bone formation in muscles, tendons, ligaments and other soft tissues.
Founded in 2022 by Chief Executive Officer Pankaj Bhargava, M.D., āshibio is a biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. The company plans to initiate a Phase 2/3 trial of its lead asset, andecaliximab, in the second half of 2024 in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation in muscle and soft tissues.
FinSMEs
20/06/2024